Efficacy and safety of transradial versus transfemoral access for mechanical thrombectomy in acute ischemic stroke: A systematic review and meta-analysis.

Interv NeuroradiolMay 21, 2025 (epub)
Clinical ResearchNeurologyCardiologyOpen access

Muhammad Aemaz Ur Rehman, Muhammad Ebaad Ur Rehman, Aqeeb Ur Rehman et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis compared transradial access (TRA) with transfemoral access (TFA) for mechanical thrombectomy in acute ischemic stroke. It included 14 studies—13 observational studies and one randomized clinical trial—with 4,973 patients. The approaches showed no significant differences in successful or first-pass recanalization, access-to-reperfusion time, favorable functional outcome, mortality, or intracranial hemorrhage. Access-site complications were less frequent with TRA (OR = 0.57; 95% CI 0.37-0.88; p = 0.01). The authors note that randomized comparative evidence remains limited.

Key findings

  • Successful recanalization did not differ significantly between TRA and TFA (OR = 0.92; 95% CI 0.66-1.27; p = 0.60).
  • First-pass recanalization was not significantly different (OR = 0.84; 95% CI 0.69-1.01, p = 0.06).
  • Access-site complications were lower with TRA (OR = 0.57; 95% CI 0.37-0.88; p = 0.01).
  • Mortality, intracranial hemorrhage, access-to-reperfusion time, and favorable functional outcome were comparable between groups.

Why it matters

The findings suggest that TRA may offer an alternative route for thrombectomy without an apparent loss of efficacy, while being associated with fewer access-site complications. This comparison is relevant when considering procedural access options, but the evidence base is predominantly observational and does not establish that the approaches are equivalent across all patients or settings.

What to keep in mind

The evidence included 13 observational studies and only one randomized clinical trial, limiting the strength of causal comparisons.

Source

Published in Interv Neuroradiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.